Business Wire

VOOPOO

Share
Innovation: The Key to VOOPOO’s Leapfrog Development

VOOPOO, a leading vape manufacturer, recently released a review on its development, revealing the underlying driving force of its success against the market backdrop of complicated international relationships, rising operation cost, intensifying competition, and product similarity – the four major innovation models, namely technological innovation to provide long-term momentum, system innovation to ensure lasting vitality, operating innovation to expand company footprint, and product innovation to increase market share.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310006062/en/

Innovation Model 1 - Technological innovation to provide long-term momentum

Technological innovation, as the foundation, provides a steady impetus for development. VOOPOO has established the strategic concept of investing in technological innovation and developing leading and original technologies.

In 2017, VOOPOO creatively developed the GENE series chips, and collaborated with DRAG to set the world record for fastest ignition speed at that time. Products were loved by more than 4 million users around the world, and are still regarded as an industry icon. In 2019, the innovative size-compatible VINCI became a new trend in Mod Pod. In 2020, DRAG X/S became one of the best-sellers in the world with its super performance and innovative metal-leather design. In 2021, VOOPOO innovatively explored the PNP/TPP/ITO vape platforms, starting to set the new technical standards in the industry.

It is with in-depth research and systematic control of market segments, keen focus on products and technologies, the pioneering and innovative spirit, and the belief in technological innovation, that VOOPOO has proceeded forward in the global market and won the trust of global users.

Since scientific and technological innovation is the primary productive force of an enterprise and the only way to achieve a global leading position, VOOPOO has set up the global innovation center with more than 500 R&D technicians working on projects at the same time. VOOPOO’s innovation model will bring the company more technological breakthroughs and promote the implementation and development of its global strategy.

Innovation Model 2 – System innovation to ensure lasting vitality

System innovation, as the soul, builds an open innovation platform, forms a sound structure from the entire group to each business department, and creates a high-value model for enterprise development. VOOPOO implements a four-level R&D system from research to product development: an innovative platform model integrating research institute, PhD researchers, expert consultants, and innovation projects covering multiple fields such as basic research, new materials, innovative atomization, HNB technology, intelligent manufacturing and modern logistics.

As of 2022, VOOPOO has applied for more than 1,000 cases of intellectual property, and has 3 R&D centers around the world covering basic research, vaping innovation, chip technology, and life science. In addition, VOOPOO has built 6 manufacturing and processing centers which are in line with Good Manufacturing Practice (GMP), covering a total area of 120,000 square meters. At the same time, VOOPOO also cooperates with many universities on innovative materials to build a forward-looking R&D system integrating production, academy and research.

In order to protect independent intellectual property rights and also stimulate creativity, VOOPOO has established a global, full-service, full-process intellectual property management system. In view of the increasing number of competitors and competitive products as well as the rampant counterfeiting, VOOPOO has applied for nearly 600 trademarks around the world, and registered defensive trademarks at the same time to prevent preemptive registration of the same or similar trademarks by third parties, so as to avoid “free riders”, thereby defending the company’s brand and reputation.

In March 2022, VOOPOO’s core trademark was included in the “2021 Guangdong Provincial Key Trademark Protection List”. It is worth noting that among the 580 trademarks on the list, only 3 are from the vaping industry.

In addition, in order to promote compliance and standardization in the global market, VOOPOO implemented the compliance strategy and set up the global compliance department early in 2019. VOOPOO was also deeply engaged in the compilation of China’s GB standard, and has submitted the American PMTA (VOOPOO is among the first batch of PMTA applicants) and involved in the European TPD3 standards.

Innovation Model 3 – Operating innovation to expand company footprint

Operating innovation, as the effective means, enables the company to be open-minded, share resources, build industrial chains, and achieve further growth.

In the Era 1.0 of operation, the upstream is about production, the midstream is about marketing, and the downstream is about channels. They are clearly distinctive to each other and each part can profit greatly. In the Era 2.0, upstream, midstream and downstream obviously become inseparable. Production, marketing and channels are closely intertwined. The ecology of the full industry chain reflects the current strategic demand of terminal consumption, channel distribution and transboundary cooperation.

Based on industry needs, VOOPOO has built the diversified strategic business structure to fully serve the needs of all parties. The company has formed a full industrial chain of vape integrating R&D, production, branding and channels, and has achieved differentiated, unique and irreproducible advantages through the integration of the industrial value chain.

At present, VOOPOO has established absolute market competitiveness on a global scale with more than 200 reserve products every year for different markets in the world. Within 3 years, it has established long-term cooperation relationships with partners in more than 70 countries and regions, and opened 6 overseas branches focusing on localized operations in the United States, UK, Indonesia, Canada and other countries. It has set up a network of 100,000 outlets around the world to shape its global brand influence.

Innovation Model 4 – Product innovation to increase market share

The VOOPOO-style innovation is ultimately product innovation, which further brings VOOPOO a more solid market position.

In the previous 2021 Ecigclick Vape Awards, VOOPOO won the Best Vape Kit For Beginners, the Best POD, the Best MOD, and the Best Sub Ohm Tank respectively with its four products ARGUS, DRAG Nano 2, DRAG 3, TPP-X. The awards reflected VOOPOO’s user-oriented consumer insights and diversified product innovation.

With the evolution of the market environment and technological innovation, users’ demands for vaping products are also constantly upgrading, and scenario-based, lightweight and multi-functional products are increasingly favored by the market. In view of this and driven by user value, VOOPOO decided to enter a new era by launching a portfolio comprising four core product series, DRAG, VINCI, ARGUS, and V, to provide users with more accurate product solutions and to continue to upgrade user experience and explore the global market.

Adhering to the four models, VOOPOO-style innovation has set a good example for the development of vaping companies.

In today’s fast-changing world, long-term thinking for the future is becoming more and more important. VOOPOO will continue to pursue the value guided by the long-term thinking. Confronted with the obstacles commonly shared by the industry, VOOPOO is taking a unique path of innovation development.

“Long-term investment in technological innovation should be planned in a long-term manner. We must dare to embrace uncertainty and strengthen cooperation with partners to truly realize the integration from technology to products,” noted EVEREST, Founder and CEO of VOOPOO.

VOOPOO firmly believes that good products are the foundation of the sustainable development of the industry. The company should be a friend of time and a pioneer of technology, and work with users and partners to jointly drive the sustainable development of the industry. The future will definitely belong to long-termism, and VOOPOO look forward to engaging more partners in its development.

WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye